Incidentally found parotid gland lesion in 18F-FDG PET/CT for staging evaluation of patients with hepatocellular carcinoma: remote possibility of metastatic tumor or second primary salivary gland malignancy

Table 2 Univariate and logistic regression analyses on parameters affecting the prevalence of parotid incidental lesion

Variables	PIL ( +) (n = 485)	PIL ( −) (n = 12,199)	P	OR (95% CI)	P
Age (years), mean ± SD	61.4 ± 9.7	58.6 ± 10.3	< 0.001	1.028 (1.019–1.037)	< 0.001
Sex, male/female	450 (92.8) / 35 (7.2)	13,865 (80.7) / 3324 (19.3)	< 0.001	3.082 (2.181–4.357)	< 0.001
HBsAg, positive/negative	156 (53.2) /137 (46.8)	1730 (14.2) / 10,469 (85.8)	< 0.001	6.891 (5.447 − 8.717)	< 0.001
Anti-HCV, positive/negative	19 (6.5) / 274 (93.5)	220 (1.8) / 11,979 (98.2)	< 0.001	3.776 (2.328–6.125)	< 0.001
AFP (µg/mL), mean ± SD	8.772 ± 84.92	7.455 ± 73.98	0.764	1 (1 − 1)	1
HCC size (cm), mean ± SD	4.5 ± 3.5	4.6 ± 8.9	0.932	0.999 (0.983 − 1.015)	0.932
SEER stage, DM( −)/DM( +)	290 (93.5) / 16 (5.5)	11,518 (94.4) / 599 (4.9)	0.656	1.173 (0.732 − 1.879)	0.507

Data expressed as number (%)
Blood tests about HBsAg, Anti-HCV, and AFP were performed within 3 months before PET/CT
AFP alpha-fetoprotein, DM distant metastasis, HBsAg hepatitis B surface antigen, HCC hepatocellular carcinoma, HCV hepatitis C virus, PIL parotid incidental lesion, SEER surveillance epidemiology and end result

ISSN: 1471-2482